<DOC>
	<DOCNO>NCT02930265</DOCNO>
	<brief_summary>It know liraglutide reduces infarct size , improve leave ventricular function , reduce myocardial stunning , play protective role myocardial ischemia-reperfusion injury patient acute myocardial infarction . But sure whether liraglutide benefit patient ischemic cardiomyopathy . This study aim explore effect Liraglutide improve cardiac function patient ischemic cardiomyopathy .</brief_summary>
	<brief_title>Clinical Study Liraglutide Improving Cardiac Function Patients With Ischemic Cardiomyopathy</brief_title>
	<detailed_description>Investigators enroll 400 patient ischemic cardiomyopathy admit Chinese PLA General Hospital . All patient enrol study collect detail baseline clinical data , include blood , enzyme ( troponin , creatine kinase ) , blood sugar , serum creatinine , blood lipid level ( LDL lipoprotein cholesterol , high density lipoprotein cholesterol , triglyceride , total cholesterol ) , brain natriuretic peptide ( BNP ) , inflammatory marker ( high sensitivity C- reactive protein , interleukin-6 ) , endothelin ( ET-1 ) , pancreas glucagon-like peptide -1 ( GLP-1 ) superoxide dismutase ( SOD ) . The investigator randomly assign eligible patient 1:1 ratio either liraglutide intervention group ( N = 200 ) control group ( N = 200 ) , liraglutide intervention group accept ischemic cardiomyopathy conventional drug liraglutide ( Novo Nordisk , specification : 18mg / 3ml ; 1.8mg subcutaneous injection 1 / day ) , Control group accept ischemic cardiomyopathy conventional drug placebo . Primary end point study main adverse cardiovascular event include Recurrent myocardial infarction , recurrent angina , revascularization , all-cause death , nonfatal myocardial infarction , nonfatal stroke , hospitalization heart failure . Secondary end point study 1 ) New York Heart Association functional class , 2 ) leave ventricular ejection fraction , 3 ) 6-minute walk test , 4 ) KCCQ clinical total score , 5 ) change blood glucose level follow-up , blood lipid level body weight</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Patients With Ischemic Cardiomyopathy : The clinical manifestation heart failure ( NYHA class IIIV grade ) , evidence cardiac dysfunction ( LVEF ≤40 % , LVEDD ≥55mm ) previous coronary angiography show one severe coronary artery stenosis . Valvular heart disease dilate cardiomyopathy patient require emergency PCI patient cardiogenic shock ; recent acute myocardial infarction one month ; recent acute stroke one month ; estimate glomerular filtration rate eGFR &lt; 30ml / min / 1.73m2 ( accord MDRD formula ) ; malignant tumor severe liver failure respiratory failure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>